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Abstract
The optic nerve and the cells that give origin to its 1.2 million axons, the retinal ganglion cells (RGCs), are particularly
vulnerable to neurodegeneration related to mitochondrial dysfunction. Optic neuropathies may range from non-syndromic
genetic entities, to rare syndromic multisystem diseases with optic atrophy such as mitochondrial encephalomyopathies, to
age-related neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease where optic nerve involvement has,
until recently, been a relatively overlooked feature. New tools are available to thoroughly investigate optic nerve function, al-
lowing unparalleled access to this part of the central nervous system. Understanding the molecular pathophysiology of RGC
neurodegeneration and optic atrophy, is key to broadly understanding the pathogenesis of neurodegenerative disorders, for
monitoring their progression in describing the natural history, and ultimately as outcome measures to evaluate therapies. In
this review, the different layers, from molecular to anatomical, that may contribute to RGC neurodegeneration and optic atro-
phy are tackled in an integrated way, considering all relevant players. These include RGC dendrites, cell bodies and axons,
the unmyelinated retinal nerve fiber layer and the myelinated post-laminar axons, as well as olygodendrocytes and astro-
cytes, looked for unconventional functions. Dysfunctional mitochondrial dynamics, transport, homeostatic control of mito-
biogenesis and mitophagic removal, as well as specific propensity to apoptosis may target differently cell types and anatomi-
cal settings. Ultimately, we can envisage new investigative approaches and therapeutic options that will speed the early
diagnosis of neurodegenerative diseases and their cure.
Introduction
It is relatively common for a neurologist looking at the fundus
oculi of a patient complaining of visual impairment to recog-
nize a pale optic disc as an isolated feature or associated with
a more complex disorder. For a long time the ‘pale optic disc’,
evidence of an atrophic optic nerve, has been poorly under-
stood and investigated by the neurologist, or discounted by
the ophthalmologist, frustrating the search for answers and
therapeutic options.
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In the last three decades, tremendous progress has been
made in understanding the genetic basis of optic neuropathies
and the molecular mechanisms leading to degeneration of reti-
nal ganglion cells (RGCs), the neuronal retinal cell type that
projects its axon to the brain, forming the optic nerve (1,2).
Currently, the two most frequent non-syndromic inherited optic
neuropathies are Leber’s hereditary optic neuropathy (LHON),
described by Albrecht von Graefe in 1858 (3) and Theodor Leber in
1871, who left his name attached (4), and dominant optic atrophy
(DOA), described by Poul Kjer in 1959 (5). Both disorders are esti-
mated to have a prevalence of approximately 1 in 30,000–65,000,
depending on the different studies and countries (6–9), and their
molecular bases have been clarified (10–13). However, optic atro-
phy may also occur for environmental reasons such as deficien-
cies of vitamin B12 or folic acid, tobacco and alcohol abuse, as
well as exposure to toxins and drugs, most frequently antibiotics,
in all cases phenocopying the genetic forms, and thus highlight-
ing similar pathogenic mechanisms (14).
Recent technological advances greatly improved the in vivo in-
vestigation of RGC function with neurophysiological exams, such
as pattern electroretinogram (PERG) and the photopic negative re-
sponse (PhNR) (15), and most importantly by direct imaging with
optical coherence tomography (OCT) (16). OCT allows for the di-
rect assessment of all retinal components, including RGCs and
their optic nerve forming axons, by quantitative evaluations of
retinal nerve fiber layer (RNFL) thickness, the macular segmenta-
tion of the ganglion cell complex (GCC), and, more recently, the
vascular components such as the choroid and the retina vascula-
ture by OCT-angiography (17–20). This tool has been fundamental
for defining the natural history of inherited optic neuropathies
(21,22) and has substantiated the frequent occurrence of optic
neuropathy in common age-related diseases such as Alzheimer’s
disease (AD) and Parkinson’s disease (PD) (23–25), thus expanding
the field of optic neuropathies to the larger area of neurodegener-
ation (13,26). This holds great promise as we can use the eye as a
window on the brain for understanding the basic molecular and
cellular mechanisms of neurodegeneration, and as a target for
neuroprotective therapies.
Retinal Ganglion Cells Vulnerability
RGCs are the usual target in LHON and DOA patients, as well as
in other optic neuropathies most frequently implying an im-
paired mitochondrial function (1,2,13). In this regard, RGCs obey
the paradigm of neurodegenerative disorders where only a sub-
population of neurons is selectively targeted by the pathological
mechanism, and RGCs display a particular vulnerability. This
vulnerability relates to the peculiar neuronal architecture of
RGCs, characterized by unique long axonal segments running
unmyelinated in the RNFL to maintain the transparency of the
retina, before these fibers turn ninety degrees and become the
optic nerve head where they cross the lamina cribrosa, and
eventually acquire their myelin sheaths and classic bundle
organization as they form the retrobulbar optic nerve (1,2,13).
Retinal Ganglion Cells Metabolic
Requirements: Homeostatic Regulation of
Mitochondrial Dynamics, Biogenesis and
Mitophagy
Not surprisingly, the large majority of inherited optic neuropa-
thies are directly or indirectly related to mitochondrial dys-
function (27,28). LHON is due to mitochondrial DNA (mtDNA)
missense mutations affecting the respiratory complex I (1,2)
and the pathogenic mechanism is ascribed to a combination
of reduced bioenergetic efficiency (29), increased reactive oxy-
gen species (ROS) production (30,31) and special propensity to
undergo apoptosis (32–34). DOA is due to heterozygous muta-
tions affecting the OPA1 gene and leading to either haploinsuf-
ficiency or a dominant negative effect (1,2,9), which
considering the major role played by OPA1 in mitochondrial
fusion, results in defective mitochondrial dynamics, altered
mitochondrial cristae and reduced bioenergetic efficiency,
mostly mediated by complex I (35–37). In both cases, there is
defective mitochondrial homeostasis implicating compensa-
tory biogenesis and the removal of damaged mitochondria by
mitophagy, altered fission/fusion balance and rates of axonal
transport, and ultimately, propensity to apoptotic cell death.
These are all themes recapitulating the major mechanisms
implicated in neurodegeneration (1,2,13,26,28,38).
Mitochondrial biogenesis and replication of mtDNA are be-
lieved to largely occur in the RGC cell body (39), where most of
the transcriptional and translational activity is carried out by
both nuclear and mitochondrial genomes, although there is
increasing evidence of an active axonal transcriptome (40).
Mitochondria are then distributed in either the dendritic tree
or transported down the long axon to the synaptic bouton
(41,42), with the characteristic trafficking of anterograde and
retrograde transport, and the asymmetric distribution of or-
ganelles, abundant in the unmyelinated proximal axonal seg-
ment in the RNFL, drastically reduced in number in the
myelinated post-laminar optic nerve (43–45). Mitochondrial
biogenesis is balanced with mitochondrial removal by mitoph-
agy in a life cycle regulated by fission and fusion (46).
Mitophagy is a hotly debated theme in neurodegeneration, in
particular in the field of PD where rare genetic forms due to
mutations in the PINK1 and Parkin genes seem to affect the ef-
ficiency of removal of damaged mitochondria (47,48). Thus,
quality control of the mitochondrial network is tightly linked
to mitochondrial biogenesis, as well as to mitochondrial dy-
namics, with a growing list of proteins that may control multi-
ple pathways in different tissues, including the ATG12-ATG3
complex (49), Parkin (50,51), Rev-erb (52) and TFEB (53,54) to
name a few, possibly responsive to the retrograde signaling
developed by dysfunctional mitochondria (55). Noticeably,
spontaneous compensatory cellular strategies based on acti-
vated mitochondrial biogenesis may be set in motion by LHON
mutations, whose efficiency might be modulated by specific
genetic backgrounds, ultimately driving the incomplete pene-
trance that characterizes LHON families (56). Estrogens, which
amongst other effects can drive mitochondrial biogenesis,
may further protect women, thus explaining male prevalence
in LHON (57,58). Conversely, accumulating evidence docu-
ments excessive mitophagy in RGCs (59) and other cell types
in DOA patients with OPA1 mutations, in particular those af-
fecting the GTPase domain leading to the syndromic forms
named DOA ‘plus’ (60,61). Interestingly, Parkin also regulates
OPA1 through linear ubiquitination of NF-jB essential modu-
lator (NEMO), establishing further links between the quality
control PINK1/Parkin axis and mitochondrial dynamics (62).
The role played by mitophagy in LHON remains incompletely
explored, even if increased mitophagic activity has been de-
scribed with complex I mtDNA mutations (63). Counter intui-
tively, excessive mitophagy might play a role in the pathogenic
mechanism of RGC neurodegeneration, as opposed to defective
mitophagy involved in the PINK1/Parkin genetic PD. Ultimately,
the homeostatic balance between mitochondrial biogenesis and
R140 | Human Molecular Genetics, 2017, Vol. 26, No. R2
mitophagy seems key to the functional architecture of RGCs, in-
volving a tight co-regulation of mitochondrial dynamics and
transport along axons and dendrites.
Retinal Ganglion Cells Dendrites: HaveWe
Been Looking in The Right Place?
The canonical view is that the RGC degeneration may affect the
soma after axonal involvement in a retrograde march (1,2).
However, limitations of in vivo studies may have lead us to miss
the early signs of RGC dysfunction that are hard to detect. The
availability of OPA1-mutant mouse models recapitulating DOA
led to the observation that remodeling of the dendritic tree, with
dendritic pruning and loss of synaptic connectivity, may be the
earliest manifestations of RGC dysfunction leading, only later, to
the stages of neurodegeneration, implying cell and axonal loss
(64,65). These findings emphasize the role of mitochondrial dy-
namics in the maintenance of neuronal architecture. The correct
distribution of mitochondria to axons and dendrites is essential
and the Ca2þ-dependent adaptor Miro1 has been identified as
the key protein for mitochondrial transport (66). A recent study
shows that Miro1 suppression leads to neurodegeneration by af-
fecting specifically dendritic complexity, but leaving unaltered
the axon (67). Interestingly, in another mouse model of complex I
deficiency, a knock-out for the nuclear encoded subunit NDUFS4,
the first event noticed to precede RGC degeneration was loss of
bipolar cells in the retina, which led to deafferentation of RGCs
and a reduction of their dendrites (68). This model, which might
resemble LHON, highlights again that early pathological events
may involve dendrites and their synaptic connections first, and
this precedes RGC and optic nerve dysfunction.
Unique Architecture of Retinal Ganglion Cell
Axons: Naked Versus Myelination and the Role
of Axonal Transport
RGC vulnerability is attributed to the unique axonal structure,
characterized by a long intraretinal segment that remains un-
myelinated (1,2). This is associated with a very asymmetrical
distribution of mitochondria along the fiber, exceedingly abun-
dant in the unmyelinated part, as opposed to the abrupt change
in mitochondrial numbers and morphology occurring as the
axons exit the eye at the lamina cribrosa and become myelin-
ated (1,2,43–45). Axonal mitochondria move bi-directionally
along microtubule tracks thanks to a complex protein machin-
ery, which includes the well-known motor proteins kinesin and
dynein, respectively involved in anterograde and retrograde
transport, but also myosins and actin, as well as adaptor pro-
teins such as Miro and Milton that in turn interact with the pro-
tein machinery involved in fission and fusion, thus strictly
connecting axonal transport and mitochondrial dynamics (69).
However, we are still missing a detailed description of how this
increasingly complex machinery is regulated or what maintains
the asymmetrical mitochondrial distribution in RGC axons. In
particular, we do not understand how anterograde and retro-
grade mitochondrial transport equilibrates with the docking
and undocking of mitochondria in the RNFL, as well as what
controls the levels of fusion/fission cycles and mitophagy in the
RGCs. It might be envisaged that the ‘kiss and run’ transient mi-
tochondrial fusion/fission cycles (70) between anterograde and
retrograde transported mitochondria may play a major role for
their maintenance, also considering distant elements such as
the synaptic boutons (71).
A few recent studies, in most cases from the field of neuro-
nal regeneration, point to new and interesting players involved
in axonal maintenance (72,73). For example, the Armadillo Repeat
Containing, X-Linked 1 (Armcx1) gene encodes a protein that is
targeted to the outer mitochondrial membrane, interacts with
Miro 1, and promotes neuronal survival and axonal regenera-
tion after injury (72). Remarkably, Armcx1 overexpression en-
hances mitochondrial transport by recruiting stationary
mitochondria in adult RGCs (72). The subacute phase of LHON
natural history, preceding the massive loss of macular RGCs
and papillomacular axons, is characterized by axonal swelling
that may be due to compensatory mitochondrial biogenesis
and stalling of axonal transport (1,2). Under such circum-
stances, Armcx1 might determine the fate of dysfunctional
RGCs with axoplasmic flow stasis. Another interesting protein,
recently demonstrated to be a regulator of axonal diameter, is
the actin-binding protein adducin (73). Abolished expression
of adducin led to progressive axonal enlargement in the optic
nerve, followed by axonal degeneration and loss in a mouse
model (73).
Axonal Myelination: The Oligodendrocytes as
Active Players
The role of oligodendrocytes and their myelination of axons re-
main relatively unexplored in studies of optic neuropathies.
Yet, in LHON and DOA the mtDNA or OPA1 mutations also affect
oligodendrocytes, possibly altering myelin turnover and ulti-
mately impinging on the pathogenic mechanisms leading to
axonal loss (1,14). Evidence of myelin loss and remodeling in
the optic nerve comes from very few post-mortem studies of
LHON and DOA patients (1,14,74–76) (Fig. 1). Similar features
have been recently observed in faithful genetic animal models
reproducing LHON and DOA (77,78). Along these lines, various
degrees of subclinical white matter pathology have been docu-
mented by in-vivo studies of LHON and DOA patients with
brain magnetic resonance imaging and spectroscopy (79).
Furthermore, in both LHON and DOA a subgroup of patients
develops a multiple sclerosis-like illness (80,81), raising the
question of whether mitochondrial dysfunction can trigger
myelin pathology (82). Optic nerve myelination and brain
white matter are vulnerable to complex I dysfunction (83,84),
and this is a common biochemical link between LHON and
DOA (29,36).
There is experimental evidence that shows metabolic interac-
tions amongst oligodendrocytes, the myelination of fibers and
the axons, and these interactions include mitochondria and en-
ergy metabolism that must sustain the functional requirements
of myelinated axons (85). Historically, animal models of selective
and reversible demyelination without damage of the underlying
axons have been based on cyanide (86), cuprizone (87), and ethid-
ium bromide (88) intoxications, all three toxicants also affecting
mitochondria by different mechanisms (14). More recent studies
of mitochondrial metabolism in oligodendrocytes indicate that
their glycolytic lactate production fuels axonal function (89,90).
Mitochondria in oligodendrocytes can populate and move into
the cytoplasmic tongues of the myelin sheaths (91). Compared to
neurons, the oligodendrocyte mitochondria are thinner and
shorter, have less cristae, are less motile and are sparsely distrib-
uted, indicative of their relatively limited oxidative phosphoryla-
tion activity and prevalent glycolytic metabolism (89–91). A new
methodological approach recently allowed for monitoring ex-vivo
the axonal ATP levels in correlation with firing of axonal action
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potentials in optic nerves acutely isolated from a transgenic
mouse expressing a fluorescent ATP-sensor (92). These experi-
ments demonstrated the high dependence of axons on ATP lev-
els, sustained by both local mitochondrial function and lactate/
pyruvate metabolism supported by glycolytic oligodendrocytes
(92). It must be noted that some studies, initially prompted by the
proteomic evidence that mitochondrial respiratory complexes
are apparently expressed in compact myelin, provided some ex-
perimental evidence leading to the currently debated proposition
that myelin might carry out local aerobic ATP production (93,94).
The strict interdependence of axons and oligodendrocytes is fur-
ther highlighted by the notion that acute demyelination induces
an increased mitochondrial population in the denuded portion of
the axon as a compensatory mechanism (95,96). Strikingly, the
opposite also seems true, as the increased axonal firing rate indu-
ces oligodendrocyte precursors to proliferate and differentiate to
mature oligodendrocytes, and ultimately increasing myelin thick-
ness (97). All considered, RGCs may be particularly vulnerable to
mitochondrial dysfunction because of their special anatomy
and physiology. They have segmental myelination that ex-
cludes the RNFL, and may be naturally designed to cope by a
fine tuning of the axonal bioenergetic needs, but RGCs may
also become rapidly imbalanced once the post-laminar myeli-
nation undergoes impaired maintenance and turnover, and all
this may trigger long-range consequences contributing to neu-
rodegeneration, (1,14).
Figure 1. Immunostained cross-sections of human optic nerve from a healthy control and a LHON patient. (A–F) Formalin-fixed paraffin embedded human optic nerves,
cross-sectional profiles, double-immunofluorescence (IF) labeling using confocal microscopy for myelin basic protein (MBP) coupled to TRITC (red) and neurofilament protein
(NF) coupled to FITC (green), and counterstained with DAPI (blue) for nuclei. (A–C) Control optic nerve from a 70-year-old female. Panel A demonstrates labeling for MBP,
panel B for NF, and panel C merges all three labels. Note the thickness of the myelin and the density of the axons. (D–F) LHON optic nerve from a 68-year-old female. Panel
D represents labeling for MBP, panel E for NF, and panel F merges all three labels. Note the decreased number of axons with myelin thinning as illustrated at arrows.
Electron microscopy cross-sectional profile of a LHON atrophic optic nerve. (G) Glutaraldehyde-fixed plastic embedded LHON optic nerve, cross-sectional profile, from a 74-
year old female, high magnification transmission electron microscopy, demonstrating a decreased density of axons with examples of myelin thinning (arrows).
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Different Patterns of Axonal Loss: Small Versus
Large
The hallmark of LHON and the other mitochondrial optic neurop-
athies is the preferential loss of small axons, affecting the papillo-
macular bundle that originates from RGCs in the macula where
small sized RGCs and axons, with thinner myelination, prevail
(98). This clinically translates into the characteristic temporal pal-
lor of the optic disc observed at fundus examination, with loss of
central vision due to a central scotoma (1,2) (Fig. 2). The axonal
caliber determines the firing rate of action potentials and ulti-
mately the energy that is needed as well as that can be provided
based on axonal surface and volume respectively (99).
Considering that increase of mitochondrial biogenesis and mass
is a key compensatory mechanism activated when mitochondria
are functionally impaired, a smaller axon is constrained in ac-
commodating these mitochondria. The axonal size, in turn, is a
major risk factor that determines the pattern of axonal degenera-
tion, with smaller axons occupying that part of the optic disc
most likely to be involved in the neurodegeneration of LHON (98).
Recently, this mechanism has been mathematically modeled,
demonstrating that the theoretical prediction perfectly fits the
histological pattern of axonal loss (100) (Fig. 2). In light of these
studies, both proteins above mentioned, Armcx1 (72) and adducin
(73), become of great interest for the possible role they might play
in LHON, and in particular could their modulation inure optic
nerves at risk in LHON from involvement?
Remarkably, in some of the age-related neurodegenerative
diseases such as AD, the pattern of axonal loss in the optic
nerve is very different, with the areas of larger sized RGCs with
their thicker axons being most affected, and this may indicate a
different pathogenic mechanism for AD-related optic neuropa-
thy (13,26) (Fig. 2).
Astrocytes, a Further Player with Some New
Roles
Astrocytes have an extraordinary broad number of different
roles in the central nervous system (101) and there is mounting
evidence of their pathogenic relevance in neurodegenerative
disease that is well beyond the scope of the present review
(102). However, in the neuroglial crosstalk there is also a novel,
non-canonical role for astrocytes that entails a bidirectional ex-
change of mitochondria between neurons and astrocytes
(103,104). It has been reported that at the optic nerve head
RGC axons form protrusions through which mitochondria are
extruded, then internalized and degraded in adjacent astrocytes
by mitophagy, a process that has been named transmitophagy
(103). The opposite trafficking may also occur as it has been re-
ported that astrocytes release mitochondria-containing parti-
cles that enter nearby neurons amplifying cell survival signals
in pathological conditions, such as in focal cerebral ischemia
(104). This bidirectional mitochondrial trafficking has obvious
broad implications in the pathogenic mechanisms of optic neu-
ropathies, and in general for neurodegeneration.
Melanopsin RGCs Resist Mitochondrial
Neurodegeneration
A special case is represented by a special subset of RGCs that
constitute about 1% of the total number of RGCs; these are a
new class of photoreceptors, the melanopsin-containing RGCs
(mRGCs). These cells, first described in 2002 (105,106), are
intrinsically photosensitive and particularly sensitive to blue
light (470 nm) due to the presence of the photopigment mela-
nopsin (107). They have large soma (up to 25 lm) and dendritic
field arborization that creates a photoreceptive net in the retina
(108), which uses an ancient phototransduction pathway simi-
lar to invertebrates, termed the rhabdomeric system, as op-
posed to the ciliary visual system of mammals (109).
Functionally, mRGCs contribute mainly the non-image forming
functions of the eye, playing a crucial role in circadian photoen-
trainment by projecting to the suprachiasmatic nucleus through
the retino-hypothalamic tract, to melatonin synthesis and its
suppression, to sleep regulation and mood (110–112). Another
mRGC pathway runs primarily through the pretectum and con-
trols the pupillary light response (110–112). Furthermore, there
is now evidence that mRGCs may also play a role in visual func-
tions (113).
Interestingly, in inherited optic neuropathies such as LHON and
DOA mRGCs are relatively spared (114), as confirmed by the preser-
vation of pupillary light reflex (115). The reasons for this resistance
to mitochondrial dysfunction are still unknown, but experimental
evidence does not support the melanopsin photopigment itself as
key (116). One possible factor protecting mRGCs from mitochon-
drial dysfunction is their large cellular size (114).
However, in other neurodegenerative disorders such as AD,
these mRGCs are preferentially lost and are affected by the typi-
cal hallmarks of amyloid pathology, possibly contributing to the
circadian imbalance described in AD patients even in the early
course of the disease (117). The different profile of RGC loss de-
scribed in AD, which is more obvious in the superior quadrant
of the optic nerve (13,117) (Fig. 2), suggests that larger size RGCs
are more vulnerable in AD, possibly explaining why mRGCs are
affected by AD pathology (see next paragraph).
Genetically Determined Optic Neuropathies:
Are They All Mitochondrial?
The list of inherited optic neuropathies, besides LHON and OPA1-
related DOA, is continuously growing with an increasing number
of genes involved, in the large majority of cases affecting mito-
chondrial functions (for reviews see 1,2,13,26,118). Preferential in-
volvement of the small axons is not always the pattern, and
other pathogenic mechanisms may occur. Optic neuropathy in
Friedreich ataxia, for example, does not obey the classic mito-
chondrial pattern, even if mitochondrial dysfunction seems to
play a role in the pathogenesis of neurodegeneration (119).
Wolfram syndrome is due to mutations in two proteins, wolfra-
min 1 and 2, which affect interorganellar communication be-
tween mitochondria and endoplasmic reticulum (ER), a hot topic
for neurodegeneration (26). Similarly, the recently reported
OPA10 gene, RTN4IP1 (reticulon 4 interacting protein 1), is also a
protein involved in mitochondrial-ER communication and reces-
sive mutations may lead to isolated or syndromic optic atrophy
(120). Optic atrophy with a diffuse pattern of axonal loss is also
described in two rare neurodegenerative disorders, autosomal
dominant cerebellar ataxia, deafness and narcolepsy (ADCA-DN)
and hereditary sensory neuropathy with dementia and hearing
loss (HSE-IN), both caused by dominant mutations in the DNA
methyltransferase1 (DNMT1) gene, which main function is to
maintain genome methylation (121). These latter disorders repre-
sent a novel model where global deregulation of gene expression
is predicted to occur due to aberrant DNA methylation, possibly
affecting some of the about 1,500 mitochondrially related pro-
teins encoded by the nuclear DNA (122).
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The Dichotomy of Optic Neuropathy in
Parkinson and Alzheimer’s Diseases
With the introduction of OCT, the assessment of optic nerve pa-
thology has been expanded to many neurodegenerative diseases,
redefining the ocular phenotype in AD (123,124). It also became
clear that different patterns of optic nerve degeneration might be
observed. For example, OCT studies in AD described a preferen-
tial RNFL thinning in the superior quadrant of the optic nerve,
which has a prevalence of large axons, and this corroborates his-
tological studies that showed that large sized RGCs are preferen-
tially lost in AD retinas (117,125,126) (Fig. 2). This pattern
resembles that of glaucoma (127) and has also been reported in
multiple system atrophy (128). Interestingly, glaucoma patients
also suffer sleep and circadian rhythm abnormalities (129) and
mRGC loss has been documented in postmortem studies (130).
Unlike AD, PD and Huntington’s disease (HD) seems to in-
volve preferentially the loss of smaller RGCs and axons as dem-
onstrated by selective RNFL thinning in the temporal sector
(24,131,132). This pattern is possibly explained by the shared
pathophysiological mechanisms of these disorders with in-
herited mitochondrial optic neuropathies, possibly affecting
complex I and mitochondrial quality control in PD (48) and mi-
tochondrial dynamics in HD (133,134).
Conclusions and Future Directions
There has been tremendous progress in the field of inherited
optic neuropathies fueled by the great diagnostic power of next
generation sequencing. This continuous refinement of the cata-
log of genetic causes provides newer details on potential path-
ogenic mechanisms that lead to RGC neurodegeneration.
The central focus remains on mitochondria and the disruption
of their many signaling and metabolic pathways that can lead
to their dysfunction. A deeper understanding for these patho-
genic mechanisms is key to designing future therapeutic strat-
egies, and it should be emphasized that, as highlighted in this
review, multiple players participate in these pathogenic mech-
anisms (Fig. 3). If these factors are not properly taken into
account, such as with gene therapy designed to correct the mi-
tochondrial genetic defect only in RGCs and not in mutant glial
cells, these therapeutic approaches may face a failure in clini-
cal trials.
Figure 2. OCT evaluation of retinal nerve fiber layer and postmortem optic nerve cross-sections from LHON patients (A, B). Panel A shows RNFL thinning at OCT evalua-
tion, more evident on the temporal quadrant, and relative sparing of the nasal quadrant of the optic nerve. Panel B shows an optic nerve cross-sectional profile display-
ing a classic profound depletion of axons on the temporal aspect of the optic nerve (asterisks) with relative preservation of axons in the supero-nasal sectors, yet with
reduced fiber density. OCT evaluation of retinal nerve fiber layer and postmortem optic nerve cross-sections from Alzheimer patients (C, D). Panel C shows RNFL thin-
ning at OCT evaluation, more evident on the supero-nasal quadrants, and sparing of the temporal quadrant of the optic nerve. Panel D shows an optic nerve cross-sec-
tional profile displaying a depletion of axons on the supero-nasal sectors of the optic nerve (asterisks) with preservation of axons in the infero-temporal sectors.
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However, inherited optic neuropathies are relatively rare ge-
netic diseases, which prompted the investigation of optic nerve
pathology in the much broader field of neurodegenerative dis-
eases including age-related PD and AD. The evidence of fre-
quent, almost ubiquitous, involvement of the optic nerve in
neurodegenerative pathologies provides an unprecedented op-
portunity to exploit the eye, in particular the neuroretina, as a
subclinical biomarker for early detection with which to follow
the natural history of these diseases. It is also a potential target/
sensor for determining therapeutic efficacy. As example of fu-
ture directions in this area is the current development of direct
and non-invasive imaging of pathologic protein deposition in
the retina such as amyloid plaques (135), as well as for apoptotic
RGC death (136). This will likely provide key tools for the moni-
toring and early diagnosis of these diseases. Furthermore, the
explosive developing field of induced pluripotent stem cells
(iPSCs) reprogrammed from primary patient-derived cell cul-
tures (137) provides the remarkable and unique opportunity to
obtain specialized terminally differentiated cells and organoids
to study ‘disease in a dish’ models, including mini-eyes and
mini-brains (138,139). These approaches hold great promise for
high throughput drug screening and the rapid development of
gene therapy, taking advantage of the powerful CRISPR/Cas9
editing technologies (Fig. 3). This would allow us to envision a
rapid translation of therapeutic options for neurodegenerative
diseases, now largely untreatable. In this respect, the eye is in a
privileged position for its greater accessibility and potential for
easier manipulation for investigations that exploit newly
developed technologies and sophisticated tools such as retinal
imaging with OCT. The ultimate goal for optic nerve regenera-
tion might not be so intangible as it has appeared until now
(140).
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